Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.04. | XFRA 8VC0,BC21,EKW0,1S90: AUSSETZUNG/SUSPENSION | 140 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGREAT PLAINS MET.... ► Artikel lesen | |
23.04. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.04.2025 | 253 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.04.2025
Aktien
1 US7866231084 AB Sagax ADR
2 US36170Y1038... ► Artikel lesen | |
22.04. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.04.2025 | 339 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.04.2025ISIN NameCA00833F3079 AFRICAN... ► Artikel lesen | |
22.04. | XFRA ISIN CHANGE | 323 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA00833F3079 African Energy Metals Inc. 22.04.2025 CA5589221004 Magma Silver Corp. 23.04.2025 Tausch 1:1CA74449Q1063 Psyence... ► Artikel lesen | |
22.04. | CSE Bulletin: Consolidation - Psyence Group Inc. (PSYG) | 304 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 21 avril/April 2025) - Psyence Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated... ► Artikel lesen | |
21.04. | Psyence Group Inc: Psyence Group 1:15 rollback | 2 | Stockwatch | ||
17.04. | Psyence Group announces share consolidation | 1 | Seeking Alpha | ||
PSYENCE GROUP Aktie jetzt für 0€ handeln | |||||
17.04. | Psyence Group Inc.: Psyence Group Announces Share Consolidation | 146 | GlobeNewswire (Europe) | TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share... ► Artikel lesen | |
09.04. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 09.04.2025 | 619 | Xetra Newsboard | The following instruments on XETRA do have their first trading 09.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 09.04.2025
Aktien
1 US83192D4025 Smartstop Self Storage... ► Artikel lesen | |
25.03. | Psyence Group Inc: Psyence associate appoints Stein to advisory board | 1 | Stockwatch | ||
25.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein | 1 | GlobeNewswire (USA) | ||
10.03. | Psyence Group Inc: Psyence associate adds Garcia-Romeu as chair of SAB | 1 | Stockwatch | ||
10.03. | Psyence Group announces collaboration with Johns Hopkins researcher | 1 | Investing.com | ||
10.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board | 190 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM"... ► Artikel lesen | |
23.12.24 | Psyence Unveils Private Placement | - | Baystreet.ca | ||
31.10.24 | Psyence Group Inc.: Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs | 175 | GlobeNewswire (Europe) | PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence... ► Artikel lesen | |
14.10.24 | Psyence Group Inc.: Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical | 169 | GlobeNewswire (Europe) | TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap... ► Artikel lesen | |
20.09.24 | Psyence Group Inc.: Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs | 892 | GlobeNewswire (Europe) | NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) (as seller), a life science biotechnology company pioneering the use of nature-derived... ► Artikel lesen | |
18.09.24 | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones | 200 | GlobeNewswire (Europe) | Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |